References
1. World Health Organization. Coronavirus. Available: https://www.who.int/health-topics/coronavirus/. Accessed 30 April 2021.
2. Worldometer. COVID-19: Coronavirus Pandemic. Available: https://www.worldometers.info/coronavirus/. Accessed 30 April 2021.
3. Centers for Disease Control and Prevention. Interim Guidelines for Collecting and Handling of Clinical Specimens for COVID-19 Testing. Available: https://www.cdc.gov/coronavirus/2019-ncov/lab/guidelines-clinical-specimens.html. Accessed 30 April 2021.
4. Yadav BK, Bihari C. Critical role of biobanks in COVID-19 pandemic. Indian Journal of Experimental Biology. 2021;59:7-10.
5. Allocca CM, Snapes E, Albert M, Bledsoe MJ, Castelhano MG, De Wilde M, et al. Biobanking in the COVID-19 era and beyond: Part 2. A set of tool Implementation case studies. BioPreservation and Biobanking. 2020;18(6):547-560.
6. Lankes HA, Makhlouf H. Biospecimen Collection During the COVID-19 Pandemic Considerations for Biobanking. American Journal of Clinical Pathology. 2021;155:55-63.
7. World Health Organization. 2020. Novel coronavirus (2019-nCoV) technical guidance: laboratory testing for 2019-nCoV in humans. World Health Organization, Geneva, Switzerland. Available: https://www.who.int/emergencies/diseases/novel-coronavirus-2019/technical-guidance/laboratory-guidance. Accessed 26 March 2021.
8. GOV.UK (Online). Guidance COVID-19: a safe handling and processing for samples in laboratories. Available: https://www.gov.uk/government/publications/wuhan-novel-coronavirus-guidance-for-clinical-diagnostic-laboratories/wuhan-novel-coronavirus-handling-and-processing-of-laboratory-specimens. Accessed 9 September 2020
9. Cloudlims, 2020. COVID-19 Clinical data Management using LIMS. Available: https://www.cloudlims.com/blog/covid-19-clinical-data-management-using-lims-html. Accessed 10 September 2020.
10. Loibner M, Langner C, Regitnig P, Gorkiewicz G. Biosafety Requirements for Autopsies of Patients with COVID-19: Example of a BSL-3 Autopsy Facility Designed for Highly Pathogenic Agents. Pathobiology. 2021;88:37–45.
11. Vaught J. Biobanking During the COVID-19 Pandemic. BioPreservation and Biobanking. 2020;18(3):153-154. https://doi.org/10.1089/bio.2020.29069.jjv.
12. Peeling RW, Boeras D, Wilder-Smith A, Sall A, Nkengasong J. Need for sustainable biobanking networks for COVID-19 and other diseases of epidemic potential. Lancet Infectious Diseases. 2020.
13. Centers for Disease Control and Prevention. Vaccines for COVID-19. Available: https://www.cdc.gov/coronavirus/2019-ncov/vaccines/index.html. Accessed 30 April 2021.
14. Moher D, Liberati A, Tetzlaff J, Altman DG, The PRISMA Group. Preferred Reporting Items for Systematic Reviews and Meta-Analyses: The PRISMA Statement. PLoS Med. 2009; 6(7):e1000097.
15. Allocca C, Bledsoe MJ, Albert M, Anisimov SV, Bravo E, Castelhano MG, et al. Biobanking in the COVID-19 Era and Beyond: Part 1. How Early Experiences Can Translate into Actionable Wisdom. BioPreservation and Biobanking. 2020;18(6):533-546.
16. Tumilasci V, Nowacki PM, Puchois P. The Promise and Plight of Biobanking Initiatives during COVID-19 pandemic: The Urgent Need to Change Existing Practices. Trans-Hit Biomarkers Whitepaper - May 8, 2020; pp.1-5.
17. Simeon-Dubach D, Henderson MK. Opportunities and Risks for Research Biobanks in the COVID-19 Era and Beyond. BioPreservation and Biobanking. 2020;18(6):506-510.
18. Christoffels A, Abayomi A. Careful governance of African biobanks. Lancet. 2020; 395(10217):29-30.
19. Parichehreh-Dizaji S, Haghpanah V. Biosafety Guidelines for COVID-19 Specimens in Biobanks. BioPreservation and Biobanking. 2020;16(6): 587-591.
20. Hofman P, Puchois P, Brest P, Lahlou H, Simeon-Dubach D. Possible consequences of the COVID-19 pandemic on the use of biospecimens from cancer biobanks for research in academia and bioindustry. Nature Medicine. 2020;26(6):809-810.
21. Cannovo N, Cingolani M, Guarino R, Fedeli P. Regulation of Biobanks in Italy. Frontiers in Pediatrics. 2020;415(8):1-5.
22. Balcom D, Wolf L, Carrico RM, Marimuthu S, Al Haddad B, Malik DA. Implementation of the University of Louisville COVID-19 Biorepository: experiences from the Center of Excellence in Infectious Diseases (CERID). University of Louisville Journal of Respiratory Infections. 2020;4:1-12.
22. Food and Agricultural Organization. 2. Standard Operating Procedures. Available: http://www.fao.org/3/w7295e/w7295e04.htm. Accessed 26 March 2021.
23. IMFBlog. COVID-19: Without Help, Low-Income Developing Countries Risk a Lost Decade. Available: https://blogs.imf.org/2020/08/27/covid-19-without-help-low-income-developing-countries-risk-a-lost-decade/. Accessed 26 March 2021.
24. de Vries J, Huijsman R. Supply chain management in health services: An overview. Supply Chain Management. 2011;16(3):159-165.
25. GAO. COVID-19: Urgent Actions Needed to Better Ensure an Effective Federal Response- Report to Congressional Committees. Available: https://files.gao.gov/reports/GAO-21-191/index.html. Accessed 30 April 2021.
26. CSCMPs Supply Chain [Quarterly]. Strategy: COVID-19 and the health care supply chain: impacts and lessons learned. Available: https://www.supplychainquarterly.com/articles/4417-covid-19-and-the-health-care-supply-chain-impacts-and-lessons-learned. Accessed 30 April 2021.
27. Miller FA, Young SB, Dobrow M, Shojania KG. Vulnerability of the medical product supply chain: the wake-up call of COVID-19. BMJ Quality & Safety. 2020;3(4).
28. Yang J-R, Liu M-T, Huang H-I, Teng H-J, Chen J-H, Li S-Y. Building the national SARS-Cov-2 Laboratory diagnostic capacity in Taiwan. Health Security. 2020;18(5). https://doi.org/ 10.1089/hs.2020.0056 [Online ahead of print].
29. Biobanking. Safety for Biobanks: Strategies for Safe COVID-19 Specimens Handling. Published 25 April 2020. Available: https://www.biobanking.com/safety-for-biobanks-strategies-for-safe-covid-19-specimens-handling/. Accessed 10 September 2020.